G.M. Graham Pharmacies Limited 04104111 false 2024-03-01 2025-02-28 2025-02-28 The principal activity of the company is that of a dispensing chemist. Digita Accounts Production Advanced 6.30.9574.0 true false true 04104111 2024-03-01 2025-02-28 04104111 2025-02-28 04104111 bus:Director1 1 2025-02-28 04104111 core:AcceleratedTaxDepreciationDeferredTax 2025-02-28 04104111 core:CurrentFinancialInstruments 2025-02-28 04104111 core:CurrentFinancialInstruments core:WithinOneYear 2025-02-28 04104111 core:Non-currentFinancialInstruments 2025-02-28 04104111 core:Non-currentFinancialInstruments core:AfterOneYear 2025-02-28 04104111 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-02-28 04104111 core:Goodwill 2025-02-28 04104111 core:PatentsTrademarksLicencesConcessionsSimilar 2025-02-28 04104111 core:CostValuation 2025-02-28 04104111 core:FurnitureFittingsToolsEquipment 2025-02-28 04104111 core:LandBuildings 2025-02-28 04104111 core:MotorVehicles 2025-02-28 04104111 core:EmployeeBenefits 2025-02-28 04104111 core:OtherProvisionsContingentLiabilities 2025-02-28 04104111 bus:SmallEntities 2024-03-01 2025-02-28 04104111 bus:AuditExemptWithAccountantsReport 2024-03-01 2025-02-28 04104111 bus:FilletedAccounts 2024-03-01 2025-02-28 04104111 bus:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 04104111 bus:RegisteredOffice 2024-03-01 2025-02-28 04104111 bus:Director1 2024-03-01 2025-02-28 04104111 bus:Director1 1 2024-03-01 2025-02-28 04104111 bus:Director2 2024-03-01 2025-02-28 04104111 bus:Director3 2024-03-01 2025-02-28 04104111 bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 04104111 bus:Agent1 2024-03-01 2025-02-28 04104111 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-03-01 2025-02-28 04104111 core:Goodwill 2024-03-01 2025-02-28 04104111 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-01 2025-02-28 04104111 core:FurnitureFittings 2024-03-01 2025-02-28 04104111 core:FurnitureFittingsToolsEquipment 2024-03-01 2025-02-28 04104111 core:LandBuildings 2024-03-01 2025-02-28 04104111 core:LeaseholdImprovements 2024-03-01 2025-02-28 04104111 core:MotorVehicles 2024-03-01 2025-02-28 04104111 core:Vehicles 2024-03-01 2025-02-28 04104111 core:EmployeeBenefits 2024-03-01 2025-02-28 04104111 core:OtherProvisionsContingentLiabilities 2024-03-01 2025-02-28 04104111 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-03-01 2025-02-28 04104111 core:OtherRelatedParties 2024-03-01 2025-02-28 04104111 core:ParentEntities 2024-03-01 2025-02-28 04104111 countries:EnglandWales 2024-03-01 2025-02-28 04104111 2024-02-29 04104111 bus:Director1 1 2024-02-29 04104111 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-02-29 04104111 core:Goodwill 2024-02-29 04104111 core:PatentsTrademarksLicencesConcessionsSimilar 2024-02-29 04104111 core:CostValuation 2024-02-29 04104111 core:FurnitureFittingsToolsEquipment 2024-02-29 04104111 core:LandBuildings 2024-02-29 04104111 core:MotorVehicles 2024-02-29 04104111 core:EmployeeBenefits 2024-02-29 04104111 core:OtherProvisionsContingentLiabilities 2024-02-29 04104111 2023-03-01 2024-02-29 04104111 2024-02-29 04104111 bus:Director1 1 2024-02-29 04104111 core:AcceleratedTaxDepreciationDeferredTax 2024-02-29 04104111 core:CurrentFinancialInstruments 2024-02-29 04104111 core:CurrentFinancialInstruments core:WithinOneYear 2024-02-29 04104111 core:Non-currentFinancialInstruments 2024-02-29 04104111 core:Non-currentFinancialInstruments core:AfterOneYear 2024-02-29 04104111 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-02-29 04104111 core:Goodwill 2024-02-29 04104111 core:PatentsTrademarksLicencesConcessionsSimilar 2024-02-29 04104111 core:FurnitureFittingsToolsEquipment 2024-02-29 04104111 core:LandBuildings 2024-02-29 04104111 core:MotorVehicles 2024-02-29 04104111 bus:Director1 1 2023-03-01 2024-02-29 04104111 bus:Director1 1 2023-02-28 iso4217:GBP xbrli:pure

Registration number: 04104111

Prepared for the registrar

G.M. Graham Pharmacies Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 28 February 2025

 

G.M. Graham Pharmacies Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 10

 

G.M. Graham Pharmacies Limited

Company Information

Directors

N D Hunt

J Jiang

Y Wang

Registered office

Fairways The Green
Newton
Sudbury
Suffolk
CO10 0QN

Accountants

Hazlewoods LLP Staverton Court
Staverton
Cheltenham
GL51 0UX

 

G.M. Graham Pharmacies Limited

(Registration number: 04104111)
Balance Sheet as at 28 February 2025

Note

2025
£

2024
£

Fixed assets

 

Intangible assets

4

2,043,409

1,820,378

Tangible assets

5

543,495

649,879

Investments

6

54,607

54,607

 

2,641,511

2,524,864

Current assets

 

Stocks

784,067

825,335

Debtors

7

5,056,231

4,284,139

Cash at bank and in hand

 

409,133

361,872

 

6,249,431

5,471,346

Creditors: Amounts falling due within one year

8

(3,353,197)

(2,931,752)

Net current assets

 

2,896,234

2,539,594

Total assets less current liabilities

 

5,537,745

5,064,458

Creditors: Amounts falling due after more than one year

8

(1,340,816)

(945,503)

Provisions

9

(315,992)

-

Deferred tax liabilities

10

(93,310)

(115,211)

Net assets

 

3,787,627

4,003,744

Capital and reserves

 

Called up share capital

10

10

Profit and loss account

3,787,617

4,003,734

Shareholders' funds

 

3,787,627

4,003,744

For the financial year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 20 November 2025 and signed on its behalf by:
 


Y Wang
Director

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Fairways The Green
Newton
Sudbury
Suffolk
CO10 0QN
England

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
 

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold improvements

10% straight line

Motor vehicles

25% reducing balance

Fixtures and fittings

25% reducing balance

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Goodwill

Goodwill is amortised over its useful life, which shall not exceed five years if a reliable estimate of the useful life cannot be made.

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Negative goodwill arising on an acquisition is recognised on the face of the balance sheet on the acquisition date and subsequently the excess up to the fair value of non-monetary assets acquired is recognised in profit or loss in the periods in which the non-monetary assets are recovered.

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Over 10 years

Website development

Over 10 years

Licence

Over 15 years

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Provisions

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.


Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.


Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 54 (2024 - 48).

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

 

4

Intangible assets

Goodwill
 £

Licences
 £

Website development
 £

Total
£

Cost

At 1 March 2024

3,704,904

229,438

65,600

3,999,942

Additions

500,000

-

-

500,000

At 28 February 2025

4,204,904

229,438

65,600

4,499,942

Amortisation

At 1 March 2024

2,086,813

76,480

16,271

2,179,564

Amortisation charge

255,158

15,296

6,515

276,969

At 28 February 2025

2,341,971

91,776

22,786

2,456,533

Carrying amount

At 28 February 2025

1,862,933

137,662

42,814

2,043,409

At 29 February 2024

1,618,091

152,958

49,329

1,820,378

 

5

Tangible assets

Leasehold improvements
£

Fixtures and fittings
 £

Motor vehicles
 £

Total
£

Cost

At 1 March 2024

287,147

1,243,279

119,049

1,649,475

Additions

3,780

17,077

-

20,857

At 28 February 2025

290,927

1,260,356

119,049

1,670,332

Depreciation

At 1 March 2024

112,281

815,001

72,314

999,596

Charge for the year

17,932

97,625

11,684

127,241

At 28 February 2025

130,213

912,626

83,998

1,126,837

Carrying amount

At 28 February 2025

160,714

347,730

35,051

543,495

At 29 February 2024

174,866

428,278

46,735

649,879

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

Included within the net book value of land and buildings above is £160,714 (2024 - £174,866) in respect of freehold land and buildings.
 

 

6

Investments

2025
£

2024
£

Investments in subsidiaries

54,607

54,607

Subsidiaries

£

Cost

At 1 March 2024

54,607

At 28 February 2025

54,607

Carrying amount

At 28 February 2025

54,607

At 29 February 2024

54,607

 

7

Debtors

Note

2025
£

2024
£

Trade debtors

 

903,420

840,021

Receivables from related parties

12

2,944,367

2,402,029

Prepayments

 

84,136

44,215

Other debtors

 

1,124,308

997,874

 

5,056,231

4,284,139

 

8

Creditors

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

11

204,378

133,003

Trade creditors

 

1,375,163

1,926,451

Amounts due to related parties

12

793,135

745,600

Taxation and social security

 

22,682

21,655

Accruals and deferred income

 

10,120

9,410

Other creditors

 

543,655

5,800

Outstanding defined contribution pension costs

 

5,368

3,289

Corporation tax liability

 

398,696

86,544

 

3,353,197

2,931,752

Note

2025
£

2024
£

Due after one year

 

Loans and borrowings

11

1,340,816

945,503

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

 

9

Provisions

NHS reimbursement
£

Dilapidations provision
£

Total
£

At 1 March 2024

-

-

-

Additional provisions

115,992

200,000

315,992

At 28 February 2025

115,992

200,000

315,992

The NHS reimbursement provision is to cover clawback of potential over-reimbursement received in the current financial year, which will be clawed back over the next 12 months.

The provision for dilapidations is management's best estimate of the likely outflow for settling the obligations upon the future termination of the lease on the branch that they relate to.

 

10

Deferred tax

Deferred tax assets and liabilities

2025

Liability
£

Accelerated capital allowances in excess of depreciation

93,310

93,310

2024

Liability
£

Accelerated capital allowances in excess of depreciation

115,211

115,211

 

11

Loans and borrowings

Current loans and borrowings

2025
£

2024
£

Bank borrowings

195,882

124,896

Other borrowings

8,496

8,107

204,378

133,003

Non-current loans and borrowings

2025
£

2024
£

Bank borrowings

1,324,747

913,659

Other borrowings

16,069

31,844

1,340,816

945,503

Bank loans are secured over the assets of the company. Hire purchase and finance leases are secured over the assets to which they relate.

 

G.M. Graham Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

 

12

Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company.
 

Transactions with directors

2025

At 1 March 2024
£

Advances to director
£

Repayments by director
£

At 28 February 2025
£

N D Hunt

Loan relating to N D Hunt, Y Wang and J Jiang

1,900,213

1,403,388

(518,439)

2,785,162

         
       

 

2024

At 1 March 2023
£

Advances to director
£

Repayments by director
£

At 29 February 2024
£

N D Hunt

Loan relating to N D Hunt, Y Wang and J Jiang

2,279,168

277,043

(655,998)

1,900,213

Summary of transactions with parent

NDH Enterprises Limited

As at the balance sheet date, the company owed NDH Enterprises Limited £793,135 (2024 - £745,600). There are no fixed repayment terms and no interest is charged on this loan.

Summary of transactions with other related parties

WYL Enterprises Limited
(Has a common director with G.M. Graham Pharmacies Limited)
At the balance sheet date, WYL Enterprises Limited owed the company £119,250 (2024 - £231,816). There are no fixed repayment terms and no interest is charged on this loan.

JJ Hunt Ltd
(Has common directors with G.M. Graham Pharmacies Limited)
At the balance sheet date, JJ Hunt Ltd owed the company £39,955 (2024 - £270,000). There are no fixed repayment terms and no interest is charged on this loan.